Mates Sharon 4

What Happened
Sharon Mates, a director of Seaport Therapeutics (SPTX), received a derivative award on 2026-04-30 covering 49,033 shares. The filing reports an acquisition price of $0.00 (derivative award), so no cash was paid by the insider at grant. This is an equity award (option) rather than an open-market purchase or sale.

Key Details

• Transaction date: April 30, 2026; Form 4 filed May 4, 2026 (appears timely within the SEC two-business-day window).
• Award: 49,033 shares (derivative/option) reported at $0.00 acquisition price; total cash value reported = $0.
• Vesting: 1/3 of the shares underlying the option vest and become exercisable on April 30, 2027; the remaining shares vest in 24 equal monthly installments thereafter, subject to continued service (footnote F1).
• Shares owned after the transaction: not provided in the excerpt of the filing.
• No indication in this filing of an immediate exercise or sale of shares (this was a grant/award).

Context
This was a time‑based option award for compensation/retention; options vest over time and do not represent an immediate cash investment by the insider. Such grants are common for directors and are primarily compensation-related rather than a direct market sentiment signal.